KENILWORTH, N.J.--(BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the Committee for Medicinal Products for Human Use (CHMP) of the European ...
RAHWAY, N.J.,--(BUSINESS WIRE)-- Merck (MRK), known as MSD outside of the United States and Canada, today announced positive topline results from the Phase 3 LITESPARK-022 trial in patients with clear ...
Late-breaking KEYNOTE-B15 data show KEYTRUDA ® (pembrolizumab) plus Padcev ® (enfortumab vedotin-ejfv) significantly improved event-free survival, overall survival and pathologic complete response ...
Patients with clear cell renal cell carcinoma had improved overall survival when treated with adjuvant Keytruda compared to placebo. Patients with clear cell renal cell carcinoma (ccRCC) experienced ...
As Merck looks for growth opportunities ahead of Keytruda’s tumble over the patent cliff, the company’s future now looks a bit brighter in the glow of two late-stage trial wins for cancer drug Welireg ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results